TNDMHealthcare · Medical DevicesThe 24 Wall Street analysts covering Tandem Diabetes Care, Inc. hold a median 12-month price target of $27 — +18.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Tandem Diabetes Care, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (88): Sales and profits are climbing, and climbing faster than before.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TNDM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +18.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Citigroup | Maintains | Neutral | $17 → $21 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $30 → $26 |
| 28 July 2026 | UBS | Assumes | Neutral | $22 → $18 |
| 15 July 2026 | Mizuho | Maintains | Neutral | $24 → $20 |
| 15 July 2026 | Mizuho | Maintains | Neutral | — |
| 23 June 2026 | Deutsche Bank | Initiates | Hold | $16 |
| 23 June 2026 | Deutsche Bank | Initiates | Hold | — |
| 1 June 2026 | Wells Fargo | Upgrade | Overweight | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 18 May 2026 | B of A Securities | Maintains | Neutral | — |
| 12 May 2026 | Benchmark | Initiates | Hold | — |
| 11 May 2026 | Barclays | Maintains | Overweight | — |
| 11 May 2026 | Truist Securities | Reiterates | Buy | — |
| 20 Apr 2026 | TD Cowen | Maintains | Buy | — |
| 9 Apr 2026 | Goldman Sachs | Maintains | Neutral | — |
| 19 Mar 2026 | Truist Securities | Upgrade | Buy | — |
| 17 Mar 2026 | Piper Sandler | Upgrade | Overweight | — |
| 2 Mar 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 23 Feb 2026 | Lake Street | Upgrade | Buy | — |
| 23 Feb 2026 | Truist Securities | Reiterates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNDM appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 60% of US stocks
Cheaper than 9% of US stocks
Cheaper than 95% of US stocks
Higher than 41% of US stocks
Higher than 70% of US stocks
Higher than 27% of US stocks
Higher than 23% of US stocks
Higher than 22% of US stocks
Higher than 35% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Tandem Diabetes Care, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
William Blair initiated coverage on Tandem Diabetes Care and Beta Bionics, noting both companies are advancing initiatives to compete in faster-growing segments of the insulin pump market.
Why it matters — The analyst initiation highlights Tandem's efforts in faster-growing insulin pump segments, which could draw attention to its competitive positioning.
Tandem Diabetes Care outlined its growth plans to expand insulin pump adoption, including a shift to pharmacy distribution in the U.S., direct sales in additional international markets, and upcoming product launches such as a tubeless version of its Tandem Mobi pump.
Why it matters — A TNDM watcher would care because these distribution changes and the planned tubeless Mobi launch could influence the company's market reach and adoption of its insulin pumps.
Tandem Diabetes shares rose 19.1% after reporting a narrower-than-expected Q2 loss, supported by higher pump shipments and a 57% gross margin, which offset a slight revenue miss versus expectations.
Why it matters — The quarter's narrower loss and strong gross margin, despite the revenue miss, point to improving profitability from core pump sales that TNDM watchers would track.
Tandem Diabetes Care reported second-quarter results featuring record sales, pump shipments, and gross margin for a second quarter. Management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.
Why it matters — TNDM watchers would note the record second-quarter sales and gross margin, alongside early progress on the pharmacy-channel reimbursement transition that could shape future growth.
Tandem Diabetes Care held its Q2 2026 earnings call, and Seeking Alpha published the transcript of the discussion with company executives.
Why it matters — Earnings call transcripts provide direct insight into Tandem's financial performance, operational updates, and management's outlook, which are key inputs for assessing the company's trajectory.
The 24 Wall Street analysts covering Tandem Diabetes Care, Inc. have a median 12-month price target of $27, with estimates ranging from $18 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering Tandem Diabetes Care, Inc., 13 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tandem Diabetes Care, Inc. 64 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Tandem Diabetes Care, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +18.7% from the last close, and Ticker Nerd's factor model ranks Tandem Diabetes Care, Inc. 64 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Tandem Diabetes Care, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNDM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $50 over the next 12 months.
Tandem Diabetes Care, Inc. returned +102.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Tandem Diabetes Care designs, develops, and commercializes advanced technology solutions for insulin-dependent diabetes management worldwide. The company's flagship products are the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology that helps optimize blood glucose levels.
The most recent item we track (Benzinga, 21 Aug 2026): "Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics". William Blair initiated coverage on Tandem Diabetes Care and Beta Bionics, noting both companies are advancing initiatives to compete in faster-growing segments of the insulin pump market.
Tandem Diabetes Care designs, develops, and commercializes advanced technology solutions for insulin-dependent diabetes management worldwide. The company's flagship products are the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology that helps optimize blood glucose levels. These durable insulin pumps work alongside continuous glucose monitoring systems, including integration with Abbott's FreeStyle Libre 3 Plus sensor. Tandem also manufactures disposable products such as infusion sets and cartridges for insulin storage and delivery. Nearly three-quarters of revenue derives from the United States, with the remainder primarily from other developed nations. The company serves individual patients with insulin-dependent diabetes across multiple distribution channels, including direct sales, pharmacy partnerships, and healthcare providers. Founded in 2006 and headquartered in San Diego, California, Tandem operates as a global leader in automated insulin delivery technology.
CEO Mr. John F. Sheridan · 2,500 employees · United States · https://www.tandemdiabetes.com